TEVA•benzinga•
Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030
Summary
Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 29, 2025 by benzinga